personally the transition from Sch 9 to 8 and onwards downwards is a timeliness matter imo. results from trials should substantiate efficacy - decision is then whether to approve under clinical conditions being mindful of potential abuse by joe public....
hmmmm....what other substances could fall into same fate one wonders
will not alter my holding of this to be great company
bring on nasdaq, $1 then $2, trial results etc etc
go you good thing
personally the transition from Sch 9 to 8 and onwards downwards...
-
- There are more pages in this discussion • 9,269 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)